Premium
Benralizumab for the treatment of severe eosinophilic asthma
Author(s) -
Chapin Steve
Publication year - 2018
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1713
Subject(s) - medicine , benralizumab , asthma , eosinophilic , dermatology , mepolizumab , eosinophil , pathology
Benralizumab (Fasenra) is a new anti‐interleukin‐5 monoclonal antibody therapy for the management of severe uncontrolled eosinophilic asthma. This article discusses its properties, clinical trial efficacy and adverse effects.